Reading BIIB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BIIB free→Reading BIIB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BIIB free→
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is neutral, and risk is moderate, while the sector backdrop is a headwind. Peer multiples imply a price about 22% above where it trades (it looks cheap on this basis); the read is fair. Key factors to watch include any potential guidance cuts from BIIB and the performance of sector bellwethers like LLY, JNJ, and ABBV. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $195.61. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $199 BIIB trades at 13× p/e, below its 17× p/e peer median. Our $257 fair value sits above the price; high confidence. Analysts: $185–$260. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 23% below a flat-multiple fair value, below our forecast of about 0%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.89x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $2.02 → $2.03 (+0.4% / 30d). 0 raised, 9 cut, 21 covering analysts.
1 upgrade, 0 downgrades / 30d, 2 maintained. 57% of analysts rate Buy.
3 PT revisions / 30d. Avg target 19.5% above current price.
Transition story with positive analyst positioning (often a turnaround setup).
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$149.
How much price usually moves either way.
On a bad day, this stock has moved -$281.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,434.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: New guidance will clarify the impact of recent acquisitions on Biogen's growth.
Confirms:Management provides guidance that shows non-GAAP EPS growth for 2027 is above 10%.
Disproves:Guidance indicates non-GAAP EPS growth for 2027 is below 5%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Advances: Merger with Apellis Pharmaceuticals
Acquisition aligns with growth and capital allocation objectives.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Completion of Acquisition or Disposition of Assets. Pursuant to the Merger Agreement, on April 14, 2026, Purchaser commenced a tender offer (the “Offer”) to acquire any and all of the issued and outstanding Shares, in exchange for (i) $41.00 per Share, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the “Cash Amount”), plus (ii) one contractual, non-transferable contingent value right per Share (each, a “CVR”) representing the right to…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$185.00 – $260.00 (median $221.50) · 12 analysts · as of 2026-06-15
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
BIIB Biogen | Above typical Show detailsSector percentile: 95 of 100 | fair | moderate |
ABBV AbbVie | Above typical Show detailsSector percentile: 86 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 81 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
14 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Met or beat guidance 100% of the last 1 guided quarters · 57.9% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Biogen aims to manage a mid-single digit percentage decline in total revenue for 2026 compared to 2025.
Biogen continues to focus on investment for growth, including business development and pipeline expansion.
Biogen completed the acquisition of Apellis Pharmaceuticals to strengthen its portfolio.
Biogen is managing a projected mid-single digit revenue decline for 2026 compared to 2025.
Why it matters: This acquisition could help Biogen in rare diseases. It may also increase revenue.
Confirms:The acquisition will close in Q4 2023. All regulatory approvals are in place.
Disproves:The acquisition will not close. This is due to lack of shareholder or regulatory approval.
Why it matters: Watching revenue from Apellis products will show how well the acquisition is doing.
Confirms:Apellis products made over $200 million last quarter.
Disproves:Apellis products made less than $100 million last quarter.
Why it matters: Good results could support Biogen's move into nephrology. This may raise investor confidence.
Confirms:The Phase 3 trial reports positive outcomes for kidney transplant patients.
Disproves:The trial results show no real benefit over current treatments.
Entry into a Material Definitive Agreement. CVR Agreement As previously disclosed, on March 31, 2026, Biogen Inc., a Delaware corporation (“Biogen”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Apellis Pharmaceuticals, Inc., a Delaware corporation (“Apellis”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Biogen (“Purchaser”). Pursuant to the Merger Agreement and in connection with the irrevocable acceptance for payment b…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. The information set forth in
Results of Operations and Financial Condition. On April 29, 2026, Biogen Inc. issued a press release announcing its results of operations and financial condition for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to
Results of Operations and Financial Condition Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted share for the first quarter of 2026 by approximately $0.19 per share. Acquired in-process research and development, upfront and milesto…